Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe announces the award of restricted share units (“RSUs”) under the Company’s amended and restated restricted share unit plan approved by shareholders at the annual general and special meeting of shareholders held on September 10, 2020 .

On February 8, 2021 , the board of directors approved a grant of RSUs to one new and one existing director, and a new officer of the Company, in accordance with the terms of the respective agreements between the Company and each individual, as set forth below.

Name

Title/Position

Number of Shares

Vesting Schedule

Juan Carlos Echeverry

Director

425,532

RSUs will vest in thirds on each of the first, second and third anniversaries of the grant date

Deborah Rosati

Director

212,766

RSUs will vest in thirds on each of the first, second and third anniversaries of the grant date

Joel Friedman

CFO

250,000

125,000 RSUs will vest as follows:

  • 62,500 RSUs on the grant date;
  • 31,250 on May 26, 2021;
  • 31,250 on November 26, 2021

The remaining 125,000 RSUs will vest as follows:

  • 50% upon the completion of a specified performance target
  • 25% on each of the first and second 6-month anniversaries thereafter

TOTAL

888,298

About Khiron Life Sciences Corp.

Khiron is a vertically integrated medical and CPG cannabis company with core operations in Latin America , and operational activity in Europe and North America . Khiron is the leading medical cannabis provider in Colombia and the first company licensed in Colombia for the cultivation, production, domestic distribution and sales, and international export of both low and high THC medical cannabis products. The Company has filled medical cannabis prescriptions in Colombia , Peru and the UK, and is positioned to commence sales of medical cannabis in Germany and Brazil in early 2021.

Leveraging wholly-owned medical clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific expertise, product innovation, and agricultural infrastructure to drive prescriptions and brand loyalty. Its Wellbeing unit launched the first branded CBD skincare brand in Colombia , with Kuida TM now marketed in multiple jurisdictions in Latin America , the US and UK. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres , together with an experienced and diverse executive team and Board of Directors.

Visit Khiron online at investors.khiron.ca and on Instagram @khironlife.

Cautionary Notes

Forward-Looking Statements

This press release may contain certain “forward-looking information” and “forward-looking statements” within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron’s control, including the risk factors discussed in Khiron’s Annual Information Form which is available on Khiron’s SEDAR profile at www.sedar.com . The forward-looking information contained in this press release is expressly qualified by this cautionary statement and is made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

Cision View original content to download multimedia: http://www.prnewswire.com/news-releases/khiron-announces-grants-of-restricted-share-units-301225467.html

SOURCE Khiron Life Sciences Corp.

News Provided by PR Newswire via QuoteMedia

The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.

With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.

Keep reading... Show less

HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its common shares have been approved for DTC full-service eligibility in the United States by the Depository Trust Company (“DTC”) and can now be both traded and serviced through DTC’s electronic book-entry system.

DTC is a subsidiary of the Depository Trust & Clearing Corp. (“DTCC”) that provides clearing and settlement services for the financial markets and settles the majority of securities transactions in the United States. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms.

Keep reading... Show less

CFN Enterprises Inc. (OTCQB: CNFN) (CFN Media) partners with FMW Media Works LLC to produce a regular series on the global cannabis markets to air on major financial news networks across the US. Initial segment features leading cannabis analyst and US Multi-State Operator (MSO)

CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the leading media network dedicated to the global legal cannabis, CBD and psychedelics industries, today announced that its inaugural news segment on the cannabis markets, “Cannabis Market Outlook for 2021,” will air on Bloomberg, Newsmax and Fox Business.

Keep reading... Show less

As “hard seltzer” beverages have sustained their popularity among consumers aged 21+ in the United States, the Company has developed a variant of its Fit Soda™ functional beverage product infused with fermented alcohol to compete in this segment, which in 2020 had approximately USD $4.1 billion in sales, with Goldman Sachs estimating that the hard seltzer market could reach USD $30 billion in sales by 2025 1 . With no sugar content and 15 calories per 12 oz / 355 ml serving, Fit Soda™ Hard could be an appealing alternative to current market leaders in the hard seltzer category. The Company intends to launch Fit Soda™ Hard in Arizona, Colorado, New Mexico, and Utah beginning in June 2021.

Koios Beverage Corp. (CSE: KBEV; OTC: KBEVF) (the “Company” or “Koios”) is pleased to announce that in June 2021 it intends to launch Fit Soda ™ Hard as a “flanker” brand to its existing Fit Soda ™ functional beverage product line. Launched on July 19, 2019 and dubbed by Koios as the “Anti-Soda”, Fit Soda ™ is a sugar-free carbonated beverage with zero calories, containing ingredients to include branched-chain amino acids and electrolytes, which have been shown to improve various aspects of one’s well-being. Fit Soda ™ has enjoyed considerable success to date, including the addition of all four flavours to Walmart’s U.S. online store and 461% growth in order volume from a Wisconsin distributor during the period of May 2020 through June 2020. Between the sustained performance of Fit Soda ™ in the United States in its second year and impressive popularity of canned “hard seltzer” among consumers aged 21+ in the alcoholic beverages category, the Company has identified a promising opportunity to produce a variant of Fit Soda™ infused with fermented alcohol produced using its in-house canning line located in the Denver, Colorado area.

Keep reading... Show less